Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
about
AME evidence series 001-The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospitalThe intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.Using Procalcitonin to Guide Antibiotic Therapy.Biomarker-guided antibiotic therapy-strengths and limitationsProcalcitionin as a diagnostic marker to distinguish upper and lower gastrointestinal perforation.Association between infection and fever in terminations of pregnancy using misoprostol: a retrospective cohort study.Procalcitonin-guided diagnosis and antibiotic stewardship revisited.Determinants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study.Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis.Influence of the postoperative inflammatory response on cognitive decline in elderly patients undergoing on-pump cardiac surgery: a controlled, prospective observational study.Comparison of Procalcitonin Guidance-Administered Antibiotics with Standard Guidelines on Antibiotic Therapy in Children with Lower Respiratory Tract Infections: A Retrospective Study in China.Measuring the impact of antimicrobial stewardship programs.Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy.Procalcitonin-guided antibiotic treatment in critically ill patients.Emerging infection and sepsis biomarkers: will they change current therapies?Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia.Determining the Clinical Utility of an Absolute Procalcitonin Value for Predicting a Positive Culture Result.What's wrong in the control of antimicrobial resistance in critically ill patients from low- and middle-income countries?Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients.Calprotectin as a Biomarker for Melioidosis Disease Progression and Management.Preventing Transmission of Multidrug-Resistant Pathogens in the Intensive Care Unit.Neutrophil CD64 expression as a longitudinal biomarker for severe disease and acute infection in critically ill patients.How Can We Optimize Antibiotic Use in the PICU?To which extent can we decrease antibiotic duration in critically ill patients?The role of procalcitonin in acute heart failure patients.Procalcitonin - Assisted Antibiotic Strategy in Sepsis.PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia.Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis.Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study.Personalized medicine of patients with respiratory infections through the measurement of specific blood biomarkers: fact or fiction?[Antibiotic Stewardship 2.0 : Individualization of therapy].Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis.Procalcitonin as a Marker of Etiology in Adults Hospitalized with Community-Acquired Pneumonia.Practice Patterns and Outcomes Associated With Procalcitonin Use in Critically Ill Patients With Sepsis.Pancreatic stone protein and soluble CD25 for infection and sepsis in an emergency department.Why biomarkers failed in sepsis.Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.Small steps beyond benchmarking.
P2860
Q28077765-4B98AE0C-8982-463F-B947-57704E39576AQ30238578-544150BB-3BFB-4F10-A65F-01E8EDD2A438Q30238953-C2ADC97D-96F3-4156-8DB5-E5789DFCE0B6Q33557838-728B8104-4527-4834-8EED-C1C5DBF91242Q33629591-F3683BF7-56EF-4384-8F74-250CEB7736FFQ33747590-A2336103-5306-4EC3-AA23-E28F8195E702Q33843450-E5151BD6-9439-46D0-ACA2-A6810C725ED1Q36241029-6A18C522-45BE-44D4-A6C1-54F6AA4FD82DQ36257991-C610C140-0E56-43DA-BFBC-5D45F74E7CAAQ37132283-2AD5F5C4-D1CF-4191-B610-67D81FA76EA1Q37685430-5C6F762E-B634-4BA7-926E-0E5C4F7F821BQ38603446-8A02E031-53C0-410E-B7D6-87E3A0DA832CQ38746435-0EDBB984-27EA-4048-A248-9953C318DA05Q38807973-4011D80B-A593-4476-8D41-D500E5E7A779Q38815453-39BF6597-98F7-4E27-B1D5-AB7DEA5DD828Q38860643-3EF08FC1-CB4A-429B-861C-CEC46CA1865CQ38929971-79D8CE01-E04B-43BC-81B9-DFCC8FA15537Q38958136-7FCCEA23-CF56-479E-B1FF-16A204ECF5D6Q38963373-3365BBCC-D967-4D66-968C-679D58D48582Q38975846-07BEA20B-D91B-4CB2-A46C-DEE7C08F941EQ39283415-FB76AAF0-0EFD-48EF-9BF5-C45BA5AA3829Q39295421-277909EA-617D-40F3-AC57-4A17A0BF9C51Q39421576-FC23F3BF-BCD7-4481-ADE5-D3276B317D6EQ39450037-FACBF0F7-B64F-4092-94D0-A4A169829A9FQ40070667-9E47A55D-87CC-4507-A38B-FA04FE87D181Q40081236-CDCE259D-B192-40E7-B84E-C88F512BDDDBQ40108118-EDBCC359-6FBD-444F-B0DB-DC5A22ABF6A2Q40113813-380462EC-C146-43BA-B402-2A87AB5B4CABQ40122073-356F949F-4E94-46C1-B3D8-089EF733628FQ40122167-E9F02DF0-769D-460A-9429-3EE4DD3E46C4Q40169961-D582AC51-1080-4B8A-BE94-F5ADE1826F17Q40174185-4AF0F4EA-B961-442E-A7D2-61D7ED2F8623Q40176582-159B2E6C-2038-4B71-945D-141D933B0C62Q40237535-CD71B10A-956D-4E6F-BB0C-7967496D9152Q40243731-7E026D67-9F01-4C7C-90ED-07F804C5C0F6Q40283690-48FE650A-A7E7-48CB-B5A6-17285A43E627Q40347415-A26998D7-CF3E-44D4-9723-CD6A83CC0436Q40543059-1E7EE225-4EB3-44B6-82A4-EA0CBEA6DB30Q41917921-D954AA84-A6D9-49F6-B790-FF6EF1458810Q42161262-D7AA849F-576E-4FE9-A3F4-47EA7B3B1265
P2860
Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Efficacy and safety of procalc ...... controlled, open-label trial.
@en
Efficacy and safety of procalc ...... controlled, open-label trial.
@nl
type
label
Efficacy and safety of procalc ...... controlled, open-label trial.
@en
Efficacy and safety of procalc ...... controlled, open-label trial.
@nl
prefLabel
Efficacy and safety of procalc ...... controlled, open-label trial.
@en
Efficacy and safety of procalc ...... controlled, open-label trial.
@nl
P2093
P1476
Efficacy and safety of procalc ...... , controlled, open-label trial
@en
P2093
Albertus Beishuizen
Anne Marie G A de Smet
Armand R Girbes
Auke C Reidinga
Bert G Loef
Evelien de Jong
Ewoudt M W van de Garde
Georg H Kluge
Gertrude C van Melsen
Hans G Krabbe
P304
P356
10.1016/S1473-3099(16)00053-0
P577
2016-03-02T00:00:00Z